$BRFH
BARFRESH FOOD GROUP INC. Stock $brfh

$brfh Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223038384 Filed on October 26, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$1.922M	$2.603M	$2.406M
YoY Change	34.31%	8.19%	24.63%
Cost Of Revenue	$1.280M	$1.690M	$3.129M
YoY Change	39.89%	-45.99%	158.72%
Gross Profit	$642.0K	$913.0K	-$723.0K
YoY Change	24.42%	-226.28%	-200.26%
Gross Profit Margin	33.4%	35.07%	-30.05%
Selling, General & Admin	$1.226M	$1.275M	$1.873M
YoY Change	-18.38%	-31.93%	81.69%
% of Gross Profit	190.97%	139.65%
Research & Development	$27.00K	$32.00K	$220.0K
YoY Change	-22.86%	-85.45%	538.61%
% of Gross Profit	4.21%	3.5%
Depreciation & Amortization	$73.00K	$102.0K	$105.0K
YoY Change	-40.16%	-2.86%
% of Gross Profit	11.37%	11.17%
Operating Expenses	$1.343M	$1.389M	$1.985M
YoY Change	-18.61%	-30.03%	61.67%
Operating Profit	-$701.0K	-$476.0K	-$2.708M
YoY Change	-38.18%	-82.42%	434.48%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$701.0K	-$480.0K	-$2.708M
YoY Change	-62.71%	-82.27%	434.48%
Income Tax
% Of Pretax Income
Net Earnings	-$701.0K	-$476.0K	-$2.708M
YoY Change	-62.71%	-82.42%	434.48%
Net Earnings / Revenue	-36.47%	-18.29%	-112.55%
Basic Earnings Per Share		-$0.04	-$0.21
Diluted Earnings Per Share	-$0.05	-$0.04	-$209.4K
COMMON SHARES
Basic Shares Outstanding	13.92M shares	13.04M shares	12.93M shares
Diluted Shares Outstanding		13.04M shares	12.93M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.891M	$1.010M	$2.837M
YoY Change	-32.66%	-64.4%	-54.69%
Cash & Equivalents	$1.891M	$1.011M	$2.837M
Short-Term Investments
Other Short-Term Assets	$67.00K	$170.0K	$348.0K
YoY Change	-76.9%	-51.15%	56.27%
Inventory	$1.214M	$748.0K	$602.0K
Prepaid Expenses
Receivables	$821.0K	$1.159M	$1.142M
Other Receivables	$160.0K	$116.0K	$77.00K
Total Short-Term Assets	$4.153M	$3.201M	$5.006M
YoY Change	-5.03%	-36.06%	-43.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$409.0K	$487.0K	$1.241M
YoY Change	5.14%	-60.76%	-32.57%
Goodwill
YoY Change
Intangibles	$241.0K	$258.0K	$323.0K
YoY Change	-21.24%	-20.12%
Long-Term Investments
YoY Change
Other Assets	$7.000K	$10.00K	$7.000K
YoY Change	0.0%	42.86%	3.7%
Total Long-Term Assets	$657.0K	$752.0K	$1.607M
YoY Change	-8.75%	-53.2%	-28.05%
TOTAL ASSETS
Total Short-Term Assets	$4.153M	$3.201M	$5.006M
Total Long-Term Assets	$657.0K	$752.0K	$1.607M
Total Assets	$4.810M	$3.953M	$6.613M
YoY Change	-5.56%	-40.22%	-40.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.670M	$1.692M	$1.802M
YoY Change	-17.86%	-6.1%	27.06%
Accrued Expenses	$85.00K	$229.0K	$315.0K
YoY Change	-70.28%	-27.3%	-58.43%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.307M	$2.660M	$2.387M
YoY Change	-10.3%	11.44%	-9.2%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities			$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.307M	$2.660M	$2.387M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.307M	$2.660M	$2.387M
YoY Change	-10.3%	11.44%	-25.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$60.80M	-$60.10M	-$56.50M
YoY Change	4.13%	6.36%
Common Stock	$0.00	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.503M	$1.293M	$4.226M
YoY Change
Total Liabilities & Shareholders Equity	$4.810M	$3.953M	$6.613M
YoY Change	-5.56%	-40.22%	-40.3%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$701.0K	-$476.0K	-$2.708M
YoY Change	-62.71%	-82.42%	434.48%
Depreciation, Depletion And Amortization	$73.00K	$102.0K	$105.0K
YoY Change	-40.16%	-2.86%
Cash From Operating Activities	-$948.0K	$60.00K	-$696.0K
YoY Change	3168.97%	-108.62%	69.77%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.830M	0.000	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-948.0K	60.00K	-696.0K
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	1.830M	0.000	0.000
Net Change In Cash	882.0K	60.00K	-696.0K
YoY Change	-3141.38%	-108.62%	24.15%
FREE CASH FLOW
Cash From Operating Activities	-$948.0K	$60.00K	-$696.0K
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$948.0K	$60.00K	-$696.0K
YoY Change	3168.97%	-108.62%	126.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001487197
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	BRFH	Value Of Shares Relinquished In Modification Of Stockbased Compensation Awards ValueOfSharesRelinquishedInModificationOfStockbasedCompensationAwards		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41228
	dei	Entity Registrant Name EntityRegistrantName	BARFRESH FOOD GROUP INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-1994406
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3600 Wilshire Blvd.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1720
	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90010
	dei	City Area Code CityAreaCode	310
	dei	Local Phone Number LocalPhoneNumber	598-7113
	dei	Entity Information Former Legal Or Registered Name EntityInformationFormerLegalOrRegisteredName	Not Applicable
	dei	Security12b Title Security12bTitle	Common stock, $0.000001 par value
	dei	Trading Symbol TradingSymbol	BRFH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13924774	shares
CY2023Q3	us-gaap	Cash Cash	1011000	usd
CY2022Q4	us-gaap	Cash Cash	2808000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	211000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1159000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	126000	usd
CY2023Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	116000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	101000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	748000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1048000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	167000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	79000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	3201000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4373000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	487000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	801000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18000	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	258000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	306000	usd
CY2023Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	7000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	7000	usd
CY2023Q3	us-gaap	Assets Assets	3953000	usd
CY2022Q4	us-gaap	Assets Assets	5505000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1692000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1534000	usd
CY2023Q3	us-gaap	Accounts Payable Underwriters Promoters And Employees Other Than Salaries And Wages Current AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent	499000	usd
CY2022Q4	us-gaap	Accounts Payable Underwriters Promoters And Employees Other Than Salaries And Wages Current AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent	499000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	229000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	286000	usd
CY2023Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	240000	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	233000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	20000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2660000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2572000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	2660000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2572000	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.000001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.000001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	400000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	400000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	23000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	23000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13104614	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13104614	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12934741	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12934741	shares
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	61388000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60905000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60095000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57972000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1293000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2933000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3953000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5505000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2603000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2406000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6205000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7731000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	1690000	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	3129000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3963000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	6807000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	913000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	-723000	usd
	us-gaap	Gross Profit GrossProfit	2242000	usd
	us-gaap	Gross Profit GrossProfit	924000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	697000	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	860000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1990000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2236000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	578000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1013000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2065000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2637000	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	114000	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	91000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	310000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	327000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	1389000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	1964000	usd
	us-gaap	Operating Expenses OperatingExpenses	4365000	usd
	us-gaap	Operating Expenses OperatingExpenses	5200000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-476000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2687000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2123000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4276000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13036000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13036000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12931000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12931000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13005000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13005000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12920000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12920000	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
	us-gaap	Net Income Loss NetIncomeLoss	-2123000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4276000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	325000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	344000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	496000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	211000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	11000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	173000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1033000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-81000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	15000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	77000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-300000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-103000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	27000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	78000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	195000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	828000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-137000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	72000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2008000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2619000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2008000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2627000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3019000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5675000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1011000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3048000	usd
	BRFH	Amounts Included In Measurement Of Lease Liabilities AmountsIncludedInMeasurementOfLeaseLiabilities	20000	usd
	BRFH	Amounts Included In Measurement Of Lease Liabilities AmountsIncludedInMeasurementOfLeaseLiabilities	60000	usd
	BRFH	Value Of Shares Relinquished In Modification Of Stockbased Compensation Awards ValueOfSharesRelinquishedInModificationOfStockbasedCompensationAwards	24000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zSj5OHgVE025" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_z9d9CagwWfy6">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets and revenues and expenses during the years reported. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zITR6670bBbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zIvRrrA9OQwb">Vendor Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is exposed to supply risk as a result of concentrations in its vendor base resulting from the use of a limited number of contract manufacturers. Purchases from the Company’s significant contract manufacturers as a percentage of all finished goods purchased were as follows:</span></p> <p id="xdx_897_eus-gaap--ScheduleOfProductInformationTableTextBlock_zisuvMjhU3p5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zZZsaAzGkvH2" style="display: none">Schedule of Company’s Contract Manufacturers of Finished Goods</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Manufacturer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerAMember_zmXrp1cYBsw8" style="width: 10%; text-align: right" title="Manufacturer percentage">55</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerAMember_zIQoVnZ53apb" style="width: 10%; text-align: right" title="Manufacturer percentage">0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerAMember_zWT6j7rDOguf" style="width: 10%; text-align: right" title="Manufacturer percentage">47</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerAMember_zzBStGClJ013" style="width: 10%; text-align: right" title="Manufacturer percentage">0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturer B</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerBMember_zvnfYFSVAHei" style="text-align: right" title="Manufacturer percentage">37</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerBMember_zAuoNVBdQ9Vb" style="text-align: right" title="Manufacturer percentage">31</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerBMember_zBeBGlbwwl6i" style="text-align: right" title="Manufacturer percentage">44</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerBMember_zW7kjLEmqCzd" style="text-align: right" title="Manufacturer percentage">28</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Manufacturer C</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerCMember_zv1RjnUKntli" style="text-align: right" title="Manufacturer percentage">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerCMember_z8q7Kk0r3Tf7" style="text-align: right" title="Manufacturer percentage">6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerCMember_zTAmABENuoxg" style="text-align: right" title="Manufacturer percentage">9</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerCMember_zm3ZYLIVSOD7" style="text-align: right" title="Manufacturer percentage">6</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturer D</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerDMember_zAuC437GZ2rk" style="text-align: right" title="Manufacturer percentage">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerDMember_zPgaNRrkgnh2" style="text-align: right" title="Manufacturer percentage">54</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerDMember_z69vKbl9Nhqf" style="text-align: right" title="Manufacturer percentage">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerDMember_zQMEiX3j8OU5" style="text-align: right" title="Manufacturer percentage">58</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Manufacturer E</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerEMember_zOWzqh1F7MO6" style="text-align: right" title="Manufacturer percentage">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerEMember_zcnvxBxY8AR2" style="text-align: right" title="Manufacturer percentage">9</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerEMember_zvGIb45Zgoa5" style="text-align: right" title="Manufacturer percentage">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerEMember_z0VeLNN5Fkc8" style="text-align: right" title="Manufacturer percentage">8</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A4_zM1hJAYxWHy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	211000	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q3	BRFH	Shipping And Handling Costs ShippingAndHandlingCosts	370000	usd
CY2022Q3	BRFH	Shipping And Handling Costs ShippingAndHandlingCosts	273000	usd
	BRFH	Shipping And Handling Costs ShippingAndHandlingCosts	932000	usd
	BRFH	Shipping And Handling Costs ShippingAndHandlingCosts	1040000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	220000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	88000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	347000	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zmRQ1UkNorl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zCkkQBDUmMvh">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications have been made to the 2022 financial statements to conform to the 2023 presentation, namely the presentation of selling, marketing and distribution expense apart from general and administrative expense in the consolidated statement of operations, the reclassification of materials shipping from selling, marketing and distribution to cost of revenue, and the presentation of the components of cash used in operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	801000	usd
CY2022Q4	us-gaap	Assets Assets	5505000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57972000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2933000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5505000	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	91000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	1964000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2687000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	327000	usd
	us-gaap	Operating Expenses OperatingExpenses	5200000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4276000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4276000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	344000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2619000	usd
CY2023Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	28000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	65000	usd
CY2023Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	720000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	983000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	748000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1048000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2956000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3035000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2469000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2234000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	487000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	801000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	102000	usd
CY2022Q3	us-gaap	Depreciation Depreciation	85000	usd
	us-gaap	Depreciation Depreciation	277000	usd
	us-gaap	Depreciation Depreciation	297000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	4000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	10000	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	13000	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	19000	usd
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-03-31
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	extended in a series of amendments through March 31, 2024
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	20000	usd
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	20000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	60000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	60000	usd
CY2022	us-gaap	Multiemployer Plan Increase In Employer Contribution Business Combination Percentage MultiemployerPlanIncreaseInEmployerContributionBusinessCombinationPercentage	0.52	pure
CY2021	us-gaap	Multiemployer Plan Increase In Employer Contribution Business Combination Percentage MultiemployerPlanIncreaseInEmployerContributionBusinessCombinationPercentage	0.42	pure
	us-gaap	Proceeds From Legal Settlements ProceedsFromLegalSettlements	100000	usd
CY2023Q3	us-gaap	Convertible Debt ConvertibleDebt	1880000	usd
	us-gaap	Debt Instrument Description DebtInstrumentDescription	The debt may be drawn in 25% increments, matures on the anniversary of the draw, bears interest at 10% per annum for the term, regardless of earlier payment or conversion, and is mandatorily convertible as to principal and interest into shares of the Company’s common stock at any time prior to maturity at the greater of $1.20 or 85% of the volume-weighted average price of the common stock for the ten trading days immediately preceding the written notice of the conversion (the “Conversion Price”).
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8503000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	211000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	173000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4276000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	4616000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2933000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2933000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	496000	usd
	BRFH	Adjustments To Additional Paid In Capital Cash Settlement Of Equitybased Compensation AdjustmentsToAdditionalPaidInCapitalCashSettlementOfEquitybasedCompensation	-24000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	11000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2123000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1293000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1293000	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	936375	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.00
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	153000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	682939	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.30
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y2M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	63545	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.50
	BRFH	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Issued SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Issued	P8Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	109388	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8.48
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	637096	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.54
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y7M6D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	576393	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.75
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y2M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P8Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.844	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.036	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.19
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	41923	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.92
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	5000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.25
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	4386	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	5.06
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	9931	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	3.33
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	32606	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.82
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	24000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2008000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1011000	usd
CY2023Q3	BRFH	Subscription Receivable SubscriptionReceivable	1880000	usd

Files In Submission

Name	View Source	Status
0001493152-23-038384-index-headers.html	Edgar Link	pending
0001493152-23-038384-index.html	Edgar Link	pending
0001493152-23-038384.txt	Edgar Link	pending
0001493152-23-038384-xbrl.zip	Edgar Link	pending
brfh-20230930.xsd	Edgar Link	pending
ex10-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
brfh-20230930_cal.xml	Edgar Link	unprocessable
brfh-20230930_def.xml	Edgar Link	unprocessable
brfh-20230930_pre.xml	Edgar Link	unprocessable
brfh-20230930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRFH
BARFRESH FOOD GROUP INC. Stock $brfh

2023 Q4 Form 10-Q Financial Statement

#000149315223038384 Filed on October 26, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRFH BARFRESH FOOD GROUP INC. Stock $brfh

2023 Q4 Form 10-Q Financial Statement

#000149315223038384 Filed on October 26, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRFH
BARFRESH FOOD GROUP INC. Stock $brfh